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MaOBJECTIVES This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability.
BACKGROUND Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Compar-
ison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been
suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should
be delayed until occurrence of clinical decompensation.
METHODS Outcomes were compared among patients who had prior hospitalization within 3 months of screening
(n ¼ 1,611 [19%]), between 3 and 6 months (n ¼ 1,009 [12%]), between 6 and 12 months (n ¼ 886 [11%]), >12 months
(n ¼ 1,746 [21%]), or who had never been hospitalized (n ¼ 3,125 [37%]).
RESULTS Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular
death or heart failure (HF) hospitalization during the course of the trial. Despite the increased risk associated with more
recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the
occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect
to cardiovascular or all-cause mortality.
CONCLUSIONS Patients with recent HF decompensation requiring hospitalization were more likely to experience
cardiovascular death or HF hospitalization than those who had never been hospitalized. Patients who were clinically
stable, as shown by a remote HF hospitalization (>3 months prior to screening) or by lack of any prior HF hospitalization,
were as likely to benefit from sacubitril/valsartan therapy as more recently hospitalized patients. (Prospective Com-
parison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF];
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ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
ARB = angiotensin receptor
blocker
HF = heart failure
NYHA = New York Heart
Association
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2all pre-specified subgroups, robust across the
spectrum of HF on the basis of comprehen-
sive risk score (3), and were unrelated to
the severity of left ventricular dysfunction
(4). Nevertheless, selection of the appro-
priate patients for transition from
angiotensin-converting enzyme (ACE) inhibi-
tors or angiotensin receptor blockers (ARB) to
sacubitril/valsartan has been the subject of
debate. Some clinicians have suggested thatonly patients with exacerbation of symptoms or hos-
pitalization despite ACE inhibitors or ARBs be
switched (5). Hospitalization for HF is a reflection of
clinical instability as well as a predictor of poor subse-
quent outcome. Prior HF hospitalization was a strong
predictor of risk of cardiovascular (CV) death and HF
hospitalizations in the CHARM (Candesartan in Heart
failure - Assessment of moRtality and Morbidity) pro-
gram, and this risk declined with time from the event
(6). To determine whether clinically stable patients
with HF and reduced ejection fraction would benefit
more from treatment with sacubitril/valsartan ther-
apy than from enalapril, we used the occurrence of
and time from a prior hospitalization for HF as the
measure of clinical stability and related this outcome
to subsequent outcomes and the efficacy of sacubitril/
valsartan.
METHODS
STUDYDESIGNANDPATIENT SELECTION. PARADIGM-HF
was a double-blind, randomized, active controlled
trial designed to compare the impact of the angio-
tensin receptor neprilysin inhibitor sacubitril/
valsartan with that of enalapril on CV mortality and
HF hospitalizations in patients with left ventricular
ejection fraction (LVEF) #40% and NYHA functional
classes II to IV HF. Patients with acute decom-
pensated HF were excluded. Details of inclusion and
exclusion and the study design have been reported
previously (7). The protocol was approved at each
participating site by an ethics committee or institu-
tional review board. All participants provided written
informed consent in accordance with established
guidelines for the protection of human subjects.
Eligible subjects had at least mildly elevated
natriuretic peptide levels (patients not hospitalized
within 12 months were required to have slightly
higher natriuretic peptide levels) and were treated
with stable doses of ACE inhibitors or ARBs and beta-
adrenergic receptor blockers for at least 4 weeks prior
to trial enrollment. Patients with symptomatic
hypotension, or an estimated glomerular filtration
rate less than 30 ml/min/1.73 m2, or potassiumconcentration > 5.2 mmol/l at screening, or history of
angioedema were excluded.
Participants underwent sequential single blind
run-in phases with enalapril at a dose of at least 10 mg
twice daily for 2 weeks followed by sacubitril/
valsartan, first given at 100 mg twice daily (sacubitril/
valsartan 49 mg/51 mg twice daily), then 200 mg
twice daily (sacubitril/valsartan, 97 mg/103 mg twice
daily) for 4 to 6 weeks. They were subsequently ran-
domized to receive enalapril, 10 mg twice daily, or
sacubitril/valsartan, 200 mg twice daily, and were
followed for a median of 27 months. History of HF
hospitalization and date of that hospitalization were
recorded on case report forms.
STATISTICAL METHODS. For this analysis, we used
presence of and time from a prior hospitalization for
HF as the measure of clinical stability. We divided
patients into 5 categories: those with prior HF
hospitalization within 3 months of screening; those
with a remote HF hospitalization defined as one of
the following 3 categories: a HF hospitalization be-
tween 3 and 6 months prior to screening; between
6 and 12 months prior to screening; >1 year prior to
screening; and those patients defined as most stable
without prior HF hospitalization. Patients with very
recent hospitalizations represented the least stable
patients. Trends in baseline characteristics across
groups were compared using linear regression and
the Cuzick nonparametric trend test and chi-squared
test for linear trend for continuous normally distrib-
uted data, continuous non-normally distributed data,
and binary/categorical data, respectively. Primary
outcome was the composite of CV death or HF hos-
pitalization, but we also assessed the outcomes CV
death and all-cause mortality. We assessed the re-
lationships among these 5 categories and risk for
events, regardless of treatment, using both
unadjusted and adjusted Cox models. We tested for
interactions between the treatment and the prior
hospitalization group with respect to these outcomes.
No correction was made for multiple testing. The
continuous relationship between time since previous
HF hospitalization and the treatment effect (sacub-
tril/valsartan-to-enalapril incidence rate ratio) for the
primary outcome was assessed among patients with
previous hospitalization. We considered modeling
time since previous HF both linearly and non-linearly
by using restricted cubic splines with up to 7 knots.
We also considered log-transformation of the time
variable. We chose the model (linear with log
transformation), which yielded the minimum Akaike
information criterion value. A p value <0.05 was
considered significant. All analyses were conducted
TABLE 1 Baseline Characteristics According to Prior Heart Failure Hospitalization*
<3 Months
(n ¼ 1,611)
3–6 Months
(n ¼ 1,009)
6–12 Months
(n ¼ 886)
>12 Months
(n ¼ 1,746)
No Prior HF
Hospitalization
(n ¼ 3,125) p Value
Age, yrs 62  12 63  11 63  11 65  11 65  11 <0.001
Females 335 (21) 212 (21) 211 (24) 345 (20) 724 (23) 0.12
Body mass index, kg/m2 28.2  5.7 28.6  5.4 28.3  5.6 28.5  5.4 27.8  5.4 0.001
NYHA functional class at randomization <0.001
1 77 (5) 45 (4) 37 (4) 60 (3) 167 (5)
2 1,085 (67) 680 (67) 581 (66) 1,209 (69) 2,351 (75)
3 438 (27) 270 (27) 254 (29) 459 (26) 591 (19)
4 8 (0) 13 (1) 13 (1) 15 (1) 11 (0)
LVEF 29  6 29  6 30  6 29  6 30  6 0.004
History of hypertension 1,214 (75) 732 (73) 639 (72) 1,236 (71) 2,101 (67) <0.001
Race 0.08
White 1,035 (64) 654 (65) 608 (69) 1,277 (73) 1,958 (63)
Black 104 (6) 66 (7) 49 (6) 87 (5) 119 (4)
Asian 329 (20) 187 (19) 142 (16) 252 (14) 592 (19)
Other 143 (9) 102 (10) 87 (10) 130 (7) 456 (15)
Region <0.001
North America 82 (5) 61 (6) 68 (8) 178 (10) 208 (7)
Latin America 259 (16) 173 (17) 144 (16) 197 (11) 660 (21)
Western Europe plus other 217 (13) 220 (22) 204 (23) 561 (32) 845 (27)
Central Europe 729 (45) 377 (37) 330 (37) 565 (32) 819 (26)
Asia-Pacific 324 (20) 178 (18) 140 (16) 245 (14) 593 (19)
SBP, mm Hg 122  15 121  15 122  16 121  15 122  16 0.78
Diabetes 533 (33) 357 (35) 332 (37) 657 (38) 1,017 (33) 0.62
Heart rate, beats/min 74  13 72  12 73  12 72  12 71  12 <0.001
Ischemic cardiomyopathy 854 (53) 601 (60) 557 (63) 1,082 (62) 1,925 (62) <0.001
Prior MI 589 (37) 440 (44) 429 (48) 815 (47) 1,353 (43) <0.001
History of AF 644 (40) 372 (37) 320 (36) 717 (41) 1,032 (33) <0.001
History of stroke 132 (8) 67 (7) 79 (9) 186 (11) 259 (8) 0.23
ICD 105 (7) 142 (14) 149 (17) 416 (24) 428 (14) <0.001
CRT 53 (3) 83 (8) 80 (9) 194 (11) 164 (5) 0.036
ACE 1,292 (80) 788 (78) 689 (78) 1,364 (78) 2,380 (76) 0.003
ARB 323 (20) 225 (22) 195 (22) 389 (22) 757 (24) 0.002
Diuretics 1,381 (86) 818 (81) 744 (84) 1,421 (81) 2,359 (75) <0.001
Beta-blockers 1,512 (94) 936 (93) 829 (94) 1,634 (94) 2,878 (92) 0.05
Digoxin 540 (34) 304 (30) 266 (30) 528 (30) 894 (29) 0.002
MRA 1,095 (68) 648 (64) 491 (55) 948 (54) 1,479 (47) <0.001
Serum creatinine, mg/dl 1.09  0.28 1.12  0.29 1.12  0.30 1.17  0.31 1.11  0.30 0.002
NT-proBNP, pg/ml [IQR] 1,884
[923, 4,035]
1,554
[824, 3,256]
1,439
[683, 3,024]
1,670
[957, 3,070]
1,565
[911, 3,003]
0.025
BNP, pg/ml [IQR] 272 [153, 579] 249 [132, 465] 221 [128, 463] 254 [168, 442] 251 [161, 446] 0.16
*Values are n (%), mean  SD, or interquartile ranges.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; ARB ¼ angiotensin receptor blocker; CRT ¼ cardiac resunchronization therapy; HF ¼ heart failure; ICD ¼
implantable cardioverter-defibrilator; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; MRA ¼ mineralcorticoid receptor antagonist; NT-proBNP ¼
N-terminal pro-B-type natriuretic peptide; SBP ¼ systolic blood pressure.
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3using Stata version 14.1 software (College Station,
Texas).
RESULTS. Of 8,399 validly randomized subjects,
5,274 patients (63%) had a prior HF hospitalization,
which occurred less than 3 months from screening in
1,611 patients (19%); between 3 and 6 months prior to
randomization in 1,009 patients (12%); between 6 and
12 months prior to randomization in 886 patients(11%); and greater than 12 months prior to randomi-
zation in 1,746 patients (21%). A total of 3,125 patients
(37%) had never been hospitalized for HF. Prior HF
hospitalization dates were not available for 6 patients
and were incorrectly or incompletely recorded for 16
patients. Baseline characteristics by prior HF hospi-
talization status and time are shown in Table 1. Par-
ticipants with more recent HF hospitalizations were
younger, had a more advanced NYHA functional class
FIGURE 1 Hazard Ratio for Primary Endpoint
Hazard ratio for primary endpoint (cardiovascular death or HF hospitalization) based on the
presence of and time from a HF hospitalization prior to screening, adjusted for baseline
characteristics which significantly differed across groups. HF ¼ heart failure.
FIGURE 2 Treatme
Forest plot shows tr
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4at baseline, had slightly lower LVEF, were more likely
to have a history of hypertension or atrial fibrillation
but were less likely to have had a prior MI, and were
more likely to have been treated with ant Effect of Sacubitril/Valsartan Therapy
eatment effects of sacubitril/valsartan (hazard ratio with 95% confidence int
eening on the outcomes of cardiovascular death or heart failure hospitalizationmineralocorticoid receptor antagonist and to have
had higher levels of N-terminal pro–B-type natriuretic
peptide (NT-proBNP).
Regardless of treatment, the risk for the primary
outcome (CV death or HF hospitalization) was higher
in patients with more recent hospitalization than for
those with no prior hospitalization in adjusted
models (<3-month hazard ratio [HR]: 1.46; 95% con-
fidence interval [CI]: 1.29 to 1.66; 3- to 6-month HR:
1.46; 95% CI: 1.26 to 1.69; 6- to 12-month HR: 1.29;
95% CI: 1.10 to 1.51; and >12-month HR: 1.26; 95% CI:
1.12 to 1.43; p < 0.001 for trend) (Figure 1). In the least
stable patients, those with a HF hospitalization
within 3 months of screening, 29% had a primary
event, and 19% died during the course of the trial. In
the most stable patients, those without prior HF
hospitalization, 20% of patients had a primary event,
and 17% died during the course of the trial. In 51% of
those most stable patients who died during the study,
the primary event was CV death with no preceding HF
hospitalization, and 60% of those CV deaths were
sudden cardiac deaths.
The efficacy of sacubitril/valsartan therapy was
not significantly different from that of enalapril
based on presence or timing of prior hospitalization
for HF (Figure 2, interaction p values ¼ 0.16, 0.66, and
0.89 for primary outcome, CV death, and all-cause
death, respectively). Specifically, compared to pa-
tients in the enalapril group, patients in theerval) based on the presence of and time from a heart failure hospi-
(left), cardiovascular death (middle), and all-cause mortality (right).
FIGURE 3 Treatment Effect on Primary Outcome
Linear regression model showing the treatment effect of sacubitril/valsartan (incidence
rate ratio with 95% confidence interval) continuously as a function of time from a heart
failure hospitalization prior to screening for the outcome of cardiovascular death or heart
failure hospitalization (left). The patients with no prior HF hospitalization are included on
the far right for comparison. Abbreviations as in Figure 1.
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5sacubitril/valsartan group had a reduction of 19% or
greater in risk of a primary endpoint and a reduction
of 25% or greater in the risk of CV death, when pa-
tients were in the most stable subgroup (no prior
hospitalization) or in the least stable subgroup (hos-
pitalization within 3 months). Figure 3 demonstrates
the continuous relationship between time since pre-
vious HF hospitalization and the treatment effect
with respect to the primary outcome. There was no
evidence of differential treatment effect across the
spectrum of time since hospitalization (p ¼ 0.90 for
interaction).
The relative incidence of adverse events of inter-
est, including symptomatic hypotension, elevation in
serum creatinine >2.5 mg/dl, or elevation in serum
potassium >6.0 mmol/liter, was similar among
patients with a recent, remote, or no prior HF hospi-
talization, with no significant interactions with
treatment (Table 2). The percentage of patients for
whom the study drug was discontinued and the per-
centage of patients with any dose reduction and the
average daily dose did not differ among patients with
a recent, remote, or no prior HF hospitalization
(Table 2). We also saw no evidence that timing from
prior hospitalization affected the likelihood of reach-
ing target dose of enalapril and sacubitril/valsartan
during the run-in phase of the trial (p ¼ 0.67).
DISCUSSION
We found that patients enrolled in PARADIGM-HF
who had never had a prior HF hospitalization or had
a remote HF hospitalization, arguably the most clin-
ically stable patients enrolled, still had high absolute
rates of CV death and of HF hospitalization during theTABLE 2 Adverse Events of Interest According to Prior HF Hospitaliz
Symptomatic
Hypotension
Elevated
Serum Creatin
>2.5 mg/dl
<3 months Enalapril 61 (7.9%) 28 (3.6%)
Sacubitril/valsartan 95 (11.5%) 23 (2.8%)
3–6 months Enalapril 43 (8.2%) 32 (6.2%)
Sacubitril/valsartan 77 (15.9%) 15 (3.1%)
6–12 months Enalapril 45 (10.0%) 11 (2.5%)
Sacubitril/valsartan 59 (13.5%) 12 (2.8%)
>12 months Enalapril 96 (10.6%) 47 (5.2%)
Sacubitril/valsartan 145 (17.2%) 40 (4.8%)
No prior HF Enalapril 142 (9.2%) 67 (4.4%)
Hospitalization Sacubitril/valsartan 210 (13.3%) 49 (3.1%)
p value for interaction 0.72 0.68
*Average daily dose during double-blind period was divided by 20 mg for the enalapril
HF ¼ heart failure.course of the trial. In these stable patients, 51% of the
first events experienced were CV death, and 60% of
these deaths were sudden cardiac deaths. With
respect to the risk of the primary endpoint and of CV
death, the patients with no prior HF hospitalization or
a remote HF hospitalization derived at least as much
benefit from treatment with sacubitril/valsartan as
with enalapril as did patients who were regarded as
clinically less stable. These findings indicate thatation
ine,
Elevated Serum
Potassium,
>6.0 mmol/l
Drug
Discontinuation
Not Due To Death
Any Dose
Reduction
Average Daily
Dose
( of target)*
51 (6.8%) 164 (21.2%) 334 (43.1%) 85  27%
38 (4.6%) 124 (14.8%) 316 (37.8%) 88  24%
39 (7.5%) 84 (16.0%) 222 (42.4%) 87  25%
18 (3.8%) 83 (17.1%) 202 (41.6%) 87  24%
24 (5.4%) 81 (18.1%) 176 (39.3%) 88  24%
21 (4.8%) 82 (18.7%) 191 (43.6%) 86  26%
45 (5.0%) 193 (21.3%) 408 (45.1%) 85  26%
30 (3.6%) 191 (22.7%) 396 (47.0%) 85  26%
75 (4.9%) 307 (19.9%) 648 (41.9%) 86  25%
74 (4.7%) 264 (16.7%) 647 (40.9%) 87  25%
0.07 0.40 0.22 0.11
arm and 400 mg for the sacubitril/valsartan arm.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Our
findings address whether clinically stable patients
would benefit from sacubitril/valsartan. We find that
while the more remote a HF hospitalization, the lower
the overall risk, there was no evidence that these
most stable patients benefit less than the least stable
patients. These results should help inform clinicians
who might consider switching patients with HF from
standard RAS inhibitors to sacubitril/valsartan.
TRANSLATIONAL OUTLOOK:While large HF trials
are often designed to assess the effectiveness and
safety of therapies in a broad group of patients, the
spectrum of patients in clinical practice can be
broader still. Further research on broader populations
incorporating patients who may not have been eligible
for PARADIGM-HF is necessary to fully appreciate the
safety and efficacy of sacubitril/valsartan in the full
spectrum of HF patients.
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6physician perceptions of clinical stability are not a
reliable approach to identifying patients who are
likely to benefit from the use of an angiotensin
receptor neprilysin inhibitor as a replacement for an
ACE inhibitor.
As was shown previously, we confirmed that a
recent HF hospitalization, a marker of clinical insta-
bility, portends increased risk for major adverse CV
events in patients with HF, and this risk declines over
time (6). Patients with no history of HF hospitaliza-
tion or only a remote history of HF hospitalization are
generally considered the most stable (particularly if
they have only Class II symptoms, as was the case in
most of the patients enrolled in the PARADIGM-HF
trial). Accordingly, clinicians may be least likely to
alter therapeutic regimens in these patients, a phe-
nomenon that has been termed “therapeutic inertia”
(8,9). Indeed, one review recently suggested that
switching from an ACE inhibitor or ARB to sacubitril/
valsartan was warranted only “if there are persistent
symptoms with recent exacerbations or hospitaliza-
tion while on.optimized treatment.” (5) Our data,
which demonstrate not only high event rates but a
superior response to sacubitril/valsartan in these
stable patients, suggest that the perception of “sta-
bility” in these patients is not a reliable indicator for
selecting patients who would benefit from intensified
treatment. This is particularly true as sudden cardiac
death is frequently the first (and last) manifestation
of instability in patients with HF who are identified
as being clinically stable.
STUDY LIMITATIONS. Several limitations of this
analysis should be noted. Results of this analysis are
most applicable to those patients who fulfilled the
inclusion and exclusion criteria of the PARADIGM-HF
trial. Indeed, patients were required to have some
elevation in natriuretic peptide levels to be enrolled,
and thus, these results cannot be interpreted as
directly applicable to HF patients without natriuretic
peptide elevation. Nevertheless, we saw no evidence
of heterogeneity in the relationship between prior HF
hospitalization and treatment effect in patients in the
lowest tertile of NT-proBNP (p interaction ¼ 0.49).
Although the overlapping 95% CIs and lack of statis-
tically significant interaction with randomized ther-
apy are suggestive of a consistent treatment benefit
across a spectrum of patients, these observations do
not prove that no differences in effectiveness exist, as
the PARADIGM-HF study was not designed with po-
wer to test for such differences. Furthermore, our
analyses were not corrected for multiple testing,
increasing the likelihood of false positive findings,
and therefore all statistically significant findings must
be interpreted in this context. Although these werepost-hoc analyses and thus need to be interpreted
with caution, these results are consistent with 2 pre-
vious analyses in which we showed that other metrics
of severity of illness in HF, the comprehensive
MAGGIC (Meta-Analysis Global Group in Chronic
Heart Failure) risk score and LVEF, also did not in-
fluence the magnitude of the superiority of sacubitril/
valsartan therapy relative to that of enalapril (3,4).
These metrics, however, are more likely to reflect
clinical severity than clinical stability.
CONCLUSIONS
We found that the patients deemed to be most clini-
cally stable by virtue of never having had a prior HF
hospitalization or having had only a remote HF hos-
pitalization prior to randomization in PARADIGM-HF
benefited at least as much from sacubitril/valsartan
therapy as less stable patients with a recent history of
clinical decompensation. These findings do not sup-
port recommendations to wait for evidence of clinical
decompensation or instability as a rational strategy
for switching patients from a conventional inhibitor
of the renin-angiotensin system to sacubitril/
valsartan.
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